Rocket Pharmaceuticals Management
Management criteria checks 2/4
Rocket Pharmaceuticals' CEO is Gaurav Shah, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is $8.01M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 1.22% of the company’s shares, worth $15.71M. The average tenure of the management team and the board of directors is 3.2 years and 6.8 years respectively.
Key information
Gaurav Shah
Chief executive officer
US$8.0m
Total compensation
| CEO salary percentage | 7.8% |
| CEO tenure | 6.8yrs |
| CEO ownership | 1.2% |
| Management average tenure | 3.2yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?
Sep 23
Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
Sep 15Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
Jun 28We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Jun 09Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
Apr 05Rocket Pharmaceuticals' Promising Path In Gene Therapy
Mar 01Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth
Nov 07Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering
Oct 03Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate
Aug 25We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate
Jul 22Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs
Jul 08Rocket Pharma: Poised For Growth In The Rare Disease Space
Jun 30Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside
Jan 30We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Nov 09Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes
Oct 01Rocket earns Evercore nod after positive data for rare genetic disease
Dec 17Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$258m |
| Jun 30 2024 | n/a | n/a | -US$253m |
| Mar 31 2024 | n/a | n/a | -US$249m |
| Dec 31 2023 | US$8m | US$625k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$253m |
| Jun 30 2023 | n/a | n/a | -US$249m |
| Mar 31 2023 | n/a | n/a | -US$237m |
| Dec 31 2022 | US$7m | US$598k | -US$222m |
| Sep 30 2022 | n/a | n/a | -US$199m |
| Jun 30 2022 | n/a | n/a | -US$192m |
| Mar 31 2022 | n/a | n/a | -US$172m |
| Dec 31 2021 | US$8m | US$590k | -US$169m |
| Sep 30 2021 | n/a | n/a | -US$186m |
| Jun 30 2021 | n/a | n/a | -US$165m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$540k | -US$140m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$89m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$4m | US$480k | -US$77m |
| Sep 30 2019 | n/a | n/a | -US$85m |
| Jun 30 2019 | n/a | n/a | -US$82m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$6m | US$414k | -US$75m |
Compensation vs Market: Gaurav's total compensation ($USD8.01M) is above average for companies of similar size in the US market ($USD5.57M).
Compensation vs Earnings: Gaurav's compensation has increased whilst the company is unprofitable.
CEO
Gaurav Shah (49 yo)
6.8yrs
Tenure
US$8,013,553
Compensation
Dr. Gaurav D. Shah, M.D., has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since Janu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$8.01m | 1.22% $ 15.7m | |
| Head of R&D | 6.8yrs | US$4.85m | 0.44% $ 5.7m | |
| Chief Technical Officer | 2.3yrs | US$4.38m | 0.062% $ 799.0k | |
| Chief Medical & Gene Therapy Officer | 6.8yrs | US$3.16m | 0.11% $ 1.4m | |
| Chief Financial Officer | less than a year | no data | no data | |
| General Counsel | 3yrs | US$1.56m | 0.070% $ 896.9k | |
| Director of Corporate Communications | no data | no data | no data | |
| Chief People Officer | 3.2yrs | no data | no data | |
| Senior VP of Clinical Safety & Chief Regulatory Officer | 4.6yrs | no data | no data | |
| Chief Business Officer | no data | US$2.82m | 0% $ 0 | |
| Chief Commercial Operations & Revenue Officer | less than a year | no data | no data |
3.2yrs
Average Tenure
49yo
Average Age
Experienced Management: RCKT's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$8.01m | 1.22% $ 15.7m | |
| Independent Director | 10.3yrs | US$399.99k | 0.13% $ 1.6m | |
| Independent Director | 6.8yrs | US$429.98k | 0% $ 0 | |
| Independent Director | 8.8yrs | US$427.49k | 0% $ 0 | |
| Independent Director | less than a year | no data | no data | |
| Chairman of the Board | 6.8yrs | US$409.99k | 0.059% $ 756.6k | |
| Independent Director | 6.8yrs | US$417.49k | 0.13% $ 1.6m | |
| Independent Non-Executive Director | 2.7yrs | US$399.99k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$409.99k | 0% $ 0 | |
| Director | 6.8yrs | US$399.99k | 0.22% $ 2.8m | |
| Independent Non- Executive Director | less than a year | US$568.70k | no data |
6.8yrs
Average Tenure
58yo
Average Age
Experienced Board: RCKT's board of directors are considered experienced (6.8 years average tenure).